1 mL BAC
50 units
resulting U-100 draw
- Concentration
- 4 mg/mL
- BAC added
- 1 mL
Shown in the diagram. Closest of these examples to 25 units.
SingleInvestigationalPhase 2Moderate confidenceSourced
ARA-290 / Cibinetide
An erythropoietin-derived tissue-protective peptide studied in small phase 2 neuropathy trials. Schedules are disease-specific and remain investigational.
Evidence context, not a personal protocol
Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.
Community-reported schedule
Community-reported · not a validated scheduleCommunity dose schedule
Community-provenance subcutaneous dosing from an authenticated research forum, about 1.3-4 mg once daily (commonly 2 mg) in roughly 30-day courses. Forum reports only, not a validated or trial-verified schedule.
Reported maximum quantityChoose the maximum quantity reported by this community line. Any earlier phase can be selected below for its arithmetic.
Reported cycle phases
Select a point for its calculation examples- Daily course (~30 days)2 mgReports span roughly 1.3-4 mg once daily, most settling near 2 mg, in ~30-day courses with about 60-day breaks. Add sodium bicarbonate or a few drops of acetic acid if the solution clouds.
Vial-aware arithmetic
Reconstitution examples, up to 3 mL
Choose the vial quantity and BAC water first. The diagram and results below update for the selected 2 mg reported quantity. Higher-strength vials may naturally land outside the 20-30 unit band.
BAC water selected
1 mL
Basic example limit: 3 mL maximum. Check the actual vial and product-specific limits.
U-100 draw50 U
20-30 U reference band
2 mL BAC
100 units
resulting U-100 draw
- Concentration
- 2 mg/mL
- BAC added
- 2 mL
3 mL BAC
150 units
resulting U-100 draw
- Concentration
- 1.333 mg/mL
- BAC added
- 3 mL
This draw exceeds a 1 mL U-100 syringe.
Formula: draw units = selected mg × BAC mL ÷ vial mg × 100. The 20-30 unit band is a measurement reference, not a recommendation. Results are mathematical examples, not preparation instructions.
Dosage and protocol evidence
Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.
Human StudySubcutaneousOnce daily for 28 days
Adults with type 2 diabetes and painful neuropathy
4 mg subcutaneously once daily for 28 days
This phase 2 schedule was followed by another 28 days of observation and is not a routine-use protocol.
View sourceCommunity GuideSubcutaneous in reportsDaily or event-timed depending on report
online research community reports
Reports include 1 mg daily for 30 days, 2.5 mg before exercise and 4 mg daily in multi-compound inflammation or pain stacks
These anecdotes are mixed and confounded. The 4 mg amount resembles a study quantity but does not reproduce the studied population, 28-day design or monitoring; raw/peptide-education/pe-tb-500-frag.md:247-249 and raw/discussions/disc-ask-med-expert.md:8935-8938.
View sourceCommunity GuideSubcutaneousOnce daily in roughly 30-day courses
authenticated research-forum (Peppys) reports and expert commentary
Subcutaneous reports cluster around 1.3-4 mg once daily (most settling near 2 mg, a few titrating to 6 mg) in roughly 30-day courses with about 60-day breaks; because the peptide tends to gel or cloud, members add plenty of bacteriostatic water plus sodium bicarbonate, or a few drops of injectable acetic acid, and aim for pH around 4-5
Forum provenance from an authenticated archive with usernames omitted. Reported quantities are consistent for neuropathic and anti-inflammatory use but are not a controlled schedule; the subcutaneous route is preferred, with intranasal noted only as a possible alternative, and quantities are not interconverted between routes.
View sourceEvidence summary
An erythropoietin-derived tissue-protective peptide studied in small phase 2 neuropathy trials. Schedules are disease-specific and remain investigational.
Protocol basis
The page reports the repeated 28-day subcutaneous research design used in small neuropathy studies, with the population and monitoring context attached.
Community provenance (Peppys)
An authenticated research-forum archive records subcutaneous ARA-290 clustering around 1.3-4 mg once daily, most reports settling near 2 mg and a few titrating as high as 6 mg, run in roughly 30-day courses with about 60-day breaks. The recurring technical theme is reconstitution: the peptide tends to gel or cloud, so members add plenty of bacteriostatic water plus sodium bicarbonate, or a few drops of injectable acetic acid, aiming for a pH near 4-5. Reports are consistent and positive for neuropathic and anti-inflammatory use, with benefit fading after discontinuation; the subcutaneous route is preferred and intranasal is mentioned only as a possible alternative, without interconverting quantities. Usernames are omitted and the planner above reproduces the arithmetic of the reported quantities rather than validating them.
What remains uncertain
Larger confirmatory trials, long-term safety, approved indications and equivalence to commercial research vials remain unresolved.
Warnings and contraindications
ARA-290 remains investigational and is not a general neuropathy treatment.
The cited daily schedule was tested for 28 days in small monitored studies.
Results from specific neuropathy populations do not establish broader use.
Shared across protocols
Supplies and general handling
Keep the universal checklist short. Product-specific labelling and source documentation always take priority over a general guide.
Research vial
Select the labelled vial quantity used in the calculation.
View Peppys vialBacteriostatic water
Use only a diluent appropriate to the research method and formulation.
View Peppys BAC waterU-100 measuring syringe
Use a new sterile device for every entry. Source locally.
Source locallyWipes and sharps container
Plan clean handling and immediate sharps disposal. Source locally.
Source locallyStorage follows the label
Do not apply a universal refrigerator rule. Follow the product, diluent and study documentation for temperature, light and expiry.
Use sterile equipment once
CDC injection-safety guidance calls for a new sterile needle and syringe for each injection and entry into a medication container.
Stability is formulation-specific
Do not infer a post-mixing lifetime from BAC water alone. Discard material when identity, integrity or sterility is in doubt.